Literature DB >> 28401407

Molecular analysis of amantadine-resistant influenza A (H1N1 pdm09) virus isolated from slum dwellers of Dhaka, Bangladesh.

Mozibur Rahman1, Sheikh Ariful Hoque2, Mohammad Ariful Islam1,3, Sabita Rezwana Rahman4.   

Abstract

Influenza is a highly contagious viral infection associated with excessive hospitalizations and deaths throughout the world. Continuous antigenic shift and drift is not only responsible for this devastating effect of influenza but also causes ineffectiveness of antiviral drugs and vaccines. In this study, we investigated the effectiveness of ribavirin, oseltamivir, and amantadine drugs in vitro against nine influenza A isolates collected during June 2012-August 2013 from different slums in Dhaka city. The effectiveness of these drugs was determined by measuring the inhibition of virus-induced cytopathic effect on MDCK cells through MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Our data showed that all nine influenza isolates (6 H1N1 pdm09 and 3 H3N2 subtypes) were completely susceptible to ribavirin (The 50% effective concentrations, EC50 3.0 µg/ml) and oseltamivir (EC50 0.35 µg/ml). When influenza A infection was challenged with amantadine drug, eight out of nine isolates (88%) demonstrated susceptibility to amantadine drug (EC50 0.30 µg/ml) while one H1N1 pdm09 isolate exhibited higher EC50 value (>10 µg/ml) beyond the cell tolerance level of drug (>5 µg/ml). Genetic analysis of transmembrane matrix protein 2 (M2), which is a target for the amantadine drug and vital for viral replication, showed a substitution of amino acid at position 31(S31 N) of that amantadine-resistant isolate indicating the possible reason of amantadine drug resistance.

Entities:  

Keywords:  Amantadine; Antiviral resistance; Influenza; MTT assay; Matrix protein

Mesh:

Substances:

Year:  2017        PMID: 28401407     DOI: 10.1007/s11262-017-1447-x

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  29 in total

1.  A history of influenza.

Authors:  C W Potter
Journal:  J Appl Microbiol       Date:  2001-10       Impact factor: 3.772

2.  Combination of ribavirin and reduning protects mice against severe pneumonia induced by H1N1 influenza a virus.

Authors:  Yuexia Ma; Wei Zhang; Zhongpeng Zhao; Min Li; Jian Liu; Yuguang Wang
Journal:  J Tradit Chin Med       Date:  2016-04       Impact factor: 0.848

3.  Computational prediction of vaccine strains for human influenza A (H3N2) viruses.

Authors:  L Steinbrück; T R Klingen; A C McHardy
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 4.  A novel approach to antiviral therapy for influenza.

Authors:  P M Colman
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

5.  Rates of spontaneous mutation among RNA viruses.

Authors:  J W Drake
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

7.  Investigation of a recent rise of dual amantadine-resistance mutations in the influenza A M2 sequence.

Authors:  Matthew G Durrant; Dennis L Eggett; David D Busath
Journal:  BMC Genet       Date:  2015-04-23       Impact factor: 2.797

8.  Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007-2008.

Authors:  Rashid Uz Zaman; A S M Alamgir; Mustafizur Rahman; Eduardo Azziz-Baumgartner; Emily S Gurley; M Abu Yushuf Sharker; W Abdullah Brooks; Tasnim Azim; Alicia M Fry; Stephen Lindstrom; Larisa V Gubareva; Xiyan Xu; Rebecca J Garten; M Jahangir Hossain; Salah Uddin Khan; Labib Imran Faruque; Syeda Shegufta Ameer; Alexander I Klimov; Mahmudur Rahman; Stephen P Luby
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

Review 9.  Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis.

Authors:  Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

10.  Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations.

Authors:  Guoying Dong; Chao Peng; Jing Luo; Chengmin Wang; Le Han; Bin Wu; Guangju Ji; Hongxuan He
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

View more
  2 in total

1.  Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway.

Authors:  Zhengfang Lin; Yinghua Li; Guifang Gong; Yu Xia; Changbing Wang; Yi Chen; Liang Hua; Jiayu Zhong; Ying Tang; Xiaomin Liu; Bing Zhu
Journal:  Int J Nanomedicine       Date:  2018-09-26

2.  Antiviral activity of iridoid glycosides extracted from Fructus Gardeniae against influenza A virus by PACT-dependent suppression of viral RNA replication.

Authors:  Shanshan Guo; Lei Bao; Chun Li; Jing Sun; Ronghua Zhao; Xiaolan Cui
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.